PMID- 37120458
OWN - NLM
STAT- MEDLINE
DCOM- 20230530
LR  - 20230629
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 200
IP  - 1
DP  - 2023 Jul
TI  - The impact of race and age on response to neoadjuvant therapy and long-term 
      outcomes in Black and White women with early-stage breast cancer.
PG  - 75-83
LID - 10.1007/s10549-023-06943-x [doi]
AB  - PURPOSE: There are a paucity of data and a pressing need to evaluate response to 
      neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black 
      women with early-stage breast cancer (EBC). METHODS: We analyzed data from 2196 
      Black and White women with EBC treated at the University of Chicago over the last 
      2 decades. Patients were divided into groups based on race and age at diagnosis: 
      Black women [Formula: see text] 40 years, White women [Formula: see text] 
      40 years, Black women [Formula: see text] 55 years, and White women [Formula: see 
      text] 55 years. Pathological complete response rate (pCR) was analyzed using 
      logistic regression. Overall survival (OS) and disease-free survival (DFS) were 
      analyzed using Cox proportional hazard and piecewise Cox models. RESULTS: Young 
      Black women had the highest risk of recurrence, which was 22% higher than young 
      White women (p = 0.434) and 76% higher than older Black women (p = 0.008). These 
      age/racial differences in recurrence rates were not statistically significant 
      after adjusting for subtype, stage, and grade. In terms of OS, older Black women 
      had the worst outcome. In the 397 women receiving NACT, 47.5% of young White 
      women achieved pCR, compared to 26.8% of young Black women (p = 0.012). 
      CONCLUSIONS: Black women with EBC had significantly worse outcomes compared to 
      White women in our cohort study. There is an urgent need to understand the 
      disparities in outcomes between Black and White breast cancer patients, 
      particularly in young women where the disparity in outcome is the greatest.
CI  - (c) 2023. The Author(s).
FAU - Terman, Elizabeth
AU  - Terman E
AD  - Pritzker School of Medicine, The University of Chicago, Chicago, USA.
FAU - Sheade, Jori
AU  - Sheade J
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA.
FAU - Zhao, Fangyuan
AU  - Zhao F
AD  - Department of Public Health Sciences, The University of Chicago, Chicago, USA.
FAU - Howard, Frederick M
AU  - Howard FM
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA.
FAU - Jaskowiak, Nora
AU  - Jaskowiak N
AD  - Department of Surgery, The University of Chicago, Chicago, USA.
FAU - Tseng, Jennifer
AU  - Tseng J
AD  - Department of Surgery, City of Hope Orange County, Irvine, USA.
FAU - Chen, Nan
AU  - Chen N
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA.
FAU - Hahn, Olwen
AU  - Hahn O
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA.
FAU - Fleming, Gini
AU  - Fleming G
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA.
FAU - Huo, Dezheng
AU  - Huo D
AD  - Department of Public Health Sciences, The University of Chicago, Chicago, USA.
FAU - Nanda, Rita
AU  - Nanda R
AUID- ORCID: 0000-0001-5248-0876
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago, Chicago, USA. rnanda@medicine.bsd.uchicago.edu.
LA  - eng
GR  - NCI-SOAR Grant#1R25CA240134-01/Foundation for the National Institutes of Health/
GR  - P20CA233307/Foundation for the National Institutes of Health/
GR  - Summer Research Program 2021/Pritzker School of Medicine/
PT  - Journal Article
DEP - 20230429
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
UOF - Res Sq. 2023 Mar 16;:. PMID: 36993723
CIN - Breast Cancer Res Treat. 2023 Aug;201(1):149-150. PMID: 37331985
MH  - Female
MH  - Humans
MH  - Black or African American
MH  - *Breast Neoplasms/ethnology/pathology
MH  - Cohort Studies
MH  - Neoadjuvant Therapy
MH  - White
MH  - *Racial Groups
MH  - *Age Factors
MH  - Adult
MH  - Middle Aged
PMC - PMC10224832
OTO - NOTNLM
OT  - Black women
OT  - Disparities
OT  - Neoadjuvant chemotherapy
OT  - Pathological complete response
OT  - Young women
COIS- Dr. Nanda has received funding from Arvinas, AstraZeneca, Celgene, Corcept 
      Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, OBI Pharma, OncoSec, 
      Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho. She serves on the advisory 
      board of AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, Infinity, iTeos, Merck, 
      OBI, Oncosec, Sanofi, Seagen. Dr. Fleming serves as an institutional PI of an 
      industry sponsored study for Roche, Iovance, Sermonix, Campugen, Celldex, 
      Corcept, AstraZeneca, Molecular Templates, Astellas, K group beta, and Pfizer. 
      The following companies supported a CME event organized by Dr. Fleming: DSI, 
      Merck, Caris, Eisai, AZ. The remaining authors have no relevant financial or 
      non-financial interests to disclose.
EDAT- 2023/04/30 00:42
MHDA- 2023/05/29 06:42
PMCR- 2023/04/29
CRDT- 2023/04/29 23:06
PHST- 2023/03/10 00:00 [received]
PHST- 2023/04/05 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/04/30 00:42 [pubmed]
PHST- 2023/04/29 23:06 [entrez]
PHST- 2023/04/29 00:00 [pmc-release]
AID - 10.1007/s10549-023-06943-x [pii]
AID - 6943 [pii]
AID - 10.1007/s10549-023-06943-x [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2023 Jul;200(1):75-83. doi: 10.1007/s10549-023-06943-x. 
      Epub 2023 Apr 29.